Impact of γ-chain cytokines on EBV-specific T cell cultures

The interplay between Epstein-Barr virus and the immune system: a rationale for adoptive cell therapy of EBV-related disorders

Myeloid antigen-presenting cell niches sustain antitumor T cells and license PD-1 blockade via CD28 costimulation

Role of CD4+ Cytotoxic T Lymphocytes in the Control of Viral Diseases and Cancer

Adoptive cell therapy against EBV-related malignancies: a survey of clinical results

Virus-specific cytotoxic CD4+ T cells for the treatment of EBV-related tumors

TIE-2 expressing monocytes in human cancers

PGE2 inhibits TIL expansion by disrupting IL-2 signalling and mitochondrial function

Exploiting the Interplay between Innate and Adaptive Immunity to Improve Immunotherapeutic Strategies for Epstein‐Barr‐Virus‐Driven Disorders

TIE-2-expressing monocytes are lymphangiogenic and associate specifically with lymphatics of human breast cancer

Immunotherapy for EBV-associated malignancies

Bone marrow-derived cells are implicated as a source of lymphatic endothelial progenitors in human breast cancer.

Survivin expression and prognostic significance in pediatric malignant peripheral nerve sheath tumors (MPNST)

ISB 1342: A first-in-class CD38 T cell engager for the treatment of relapsed refractory multiple myeloma.

IGKV3 Proteins as Candidate “Off-the-Shelf” Vaccines for Kappa-Light Chain–Restricted B-Cell Non-Hodgkin Lymphomas

A BARF1-specific mAb as a new immunotherapeutic tool for the management of EBV-related tumors

Differential down-modulation of HLA class I and II molecule expression on human tumor cell lines upon in vivo transfer

A combined computational and experimental approach to successfully predict the behavior of metastatic tumor-associated macrophages in human breast cancer

Anti-BARF1 monoclonal antibody

IGKV3 proteins as candidate “off-the-shelf” vaccines for kappa-light chain-restricted B cell non-Hodgkin’s lymphomas (156.15)